| Autor: |
Maze, Dawn, Arcasoy, Murat O., Henrie, Ryan, Cerquozzi, Sonia, Kamble, Rammurti, Al-Hadidi, Samer, Yacoub, Abdulraheem, Singh, Anurag K., Elsawy, Mahmoud, Sirhan, Shireen, Smith, Elliot, Marcoux, Curtis, Viswabandya, Auro, Daly, Andrew, Sibai, Hassan, McNamara, Caroline, Shi, Yuliang, Xu, Wei, Lajkosz, Katherine, Foltz, Lynda, Gupta, Vikas |
| Zdroj: |
Bone Marrow Transplantation; 20240101, Issue: Preprints p1-7, 7p |
| Abstrakt: |
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF) and is recommended for patients with higher risk disease. However, there is a risk of early mortality, and optimal timing is unknown. JAK inhibitor (JAKi) therapy may offer durable improvement in symptoms, splenomegaly and quality of life. The aim of this multicentre, retrospective observational study was to compare outcomes of patients aged 70 years or below with MF in chronic phase who received upfront JAKi therapy vs. upfront HCT in dynamic international prognostic scoring system (DIPSS)-stratified categories. For the whole study cohort, median overall survival (OS) was longer for patients who received a JAKi vs. upfront HCT, 69 (95% CI 57–89) vs. 42 (95% CI 20–not reached, NR) months, respectively (p= 0.01). In patients with intermediate-2 and high-risk disease, median OS was 55 (95% CI 36–73) months with JAKi vs. 36 (95% CI 20–NR) months for HCT (p= 0.27). An upfront HCT strategy was associated with early mortality and difference in median OS was not observed in any risk group by 5 years of follow-up. Within the limitations of a retrospective observational study, we did not observe any benefit of a universal upfront HCT approach for higher-risk MF. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink